Achillion-Logo-150 (4).jpg
Achillion Reports 2015 Fourth Quarter and Year-End Financial Results
February 25, 2016 06:05 ET | Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and twelve month periods ending December 31, 2015. ...
Achillion-Logo-150 (4).jpg
Achillion Initiates Phase 1 Study of ACH-4471, First Orally-Administered Small Molecule Complement Factor D Inhibitor
February 11, 2016 06:05 ET | Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Feb. 11, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the initiation of a phase 1 study with ACH-4471, the Company’s first...
Achillion-Logo-150 (4).jpg
Achillion Announces Appointments of Martha Manning as General Counsel and Amy Jennings as Head of Regulatory Affairs
February 03, 2016 06:05 ET | Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the addition of two members to the senior management team. Martha Manning, Esq.,...
Achillion-Logo-150 (4).jpg
Achillion Announces Upcoming Oral Presentation at the 57th Annual Meeting of the American Society of Hematology and Nomination of ACH-4471, a Novel Small Molecule Factor D Inhibitor, for Clinical Development
December 05, 2015 17:00 ET | Achillion Pharmaceuticals, Inc.
- Presentation will highlight ACH-4471, a highly potent, specific, and orally-administered factor D inhibitor, and preclinical data on its ability to block hemolysis of paroxysmal nocturnal...
Akari Logo (1).jpg
Akari Therapeutics Announces Upcoming Data Presentations at the 57th American Society of Hematology Annual Meeting
November 05, 2015 09:44 ET | Akari Therapeutics Plc
NEW YORK and LONDON, Nov. 05, 2015 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, development-stage biopharmaceutical company, announced today that new data on...